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Abstract
Background: Pooling strategies have been used to reduce the costs of polymerase
chain reaction based screening for acute HIV infection in populations where the
prevalence of acute infection is low (<1%). Only limited research has been done for
conditions where the prevalence of screening positivity is higher (>1%).
Methods and Results: We present data on a variety of pooling strategies that
incorporate the use of PCR-based quantitative measures to monitor for virologic
failure among HIV-infected patients receiving antiretroviral therapy. For a prevalence
of virologic failure between 1% and 25%, we demonstrate relative efficiency and
accuracy of various strategies. These results could be used to choose the best strategy
based on the requirements of individual laboratory and clinical settings, such as
required turnaround time of results, and availability of resources.
Conclusions: Virologic monitoring during antiretroviral therapy is not currently
being performed in many resource constrained settings largely because of costs. The
presented pooling strategies may be used to make such monitoring feasible and to
optimally limit the development and transmission of HIV drug resistance in resource
constrained settings. They may also be used to design efficient pooling strategies for
other settings where screening involves quantitative measures.
1. INTRODUCTION
In high-resourced settings, the failure of antiretroviral therapy (ART) to suppress
HIV replication (i.e. virologic failure) while a patient is receiving ART is detected by
the regular monitoring of HIV RNA levels in the blood (viral loads) (Hammer et al.,
2006; Haubrich et al., 2001; Hughes et al., 1997). Viral loads are not preformed
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regularly in resource-constrained settings, where changes in CD4 cell count are used
as a surrogate, although CD4 –based criteria have been shown to be insensitive in
detecting virologic failure during ART (Bisson et al., 2008; Bisson et al., 2006;
Fiscus et al., 2006; Moore et al., 2006; Petti et al., 2006). It is, therefore, imperative
to develop and implement less expensive methods to monitor for viral replication
during ART in resource-constrained settings to limit the development and
transmission of drug resistant HIV (Calmy et al., 2007; Durant et al., 1999; Miller
and Larder, 2001; Phillips et al., 2008; Smith and Schooley, 2008).
Various efforts demonstrated that screening for HIV RNA among people
presenting for HIV testing or blood donation can be used efficiently to identify
individuals who were acutely infected with HIV despite a negative HIV antibody test,
since individuals testing during the window period between acute HIV infection and
seroconversion will escape routine detection (Busch et al., 2005; Patterson et al.,
2007; Pilcher et al., 2005; Pilcher et al., 2002). Because testing for HIV RNA in each
blood sample would be expensive, a commonly used strategy is to pool blood
samples from a group of individuals and perform one HIV RNA assay on a pooled
sample (Busch, et al., 2005; Patterson, et al., 2007; Pilcher, et al., 2005; Pilcher, et al.,
2002). If the pool tests positive, individual samples or pools of smaller size might be
tested again to identify affected individuals. Performance and advantages of different
pooling strategies for screening purposes have been extensively investigated. In a
landmark paper Dorfman (1943) calculated the optimal pool size for a prevalence
ranging from 1% to 30% for a single stage pooling algorithm. Hammick and
Gastwirth (1994) suggest to obtain two samples per individual an form two
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independent sets of groupings to estimate the prevalence of HIV while preserving
confidentiality. An advantage of this procedure is that it can be efficient for a
prevalence of up to about 30%. Brookmeyer (1999) developed an estimator of disease
prevalence and its variance for multistage pooling studies. Westreich et al (2008)
investigate the performance of three different pooling strategies (two hierarchical and
one matrix based approach) to acute HIV infection. Kim et al. (2007) derive and
compare operating characteristics of hierarchical as well as square array-based testing
algorithms in the presence of testing error. For additional references see
(Brookmeyer, 1999; Hammick and Gastwirth, 1994; Kim et al., 2007; Westreich et
al., 2008)}. Nevertheless, all of the existing work is based on settings where the
outcome is binary (disease versus no disease). Also, the testing for HIV RNA in
blood samples pooled from patients receiving ART to identify instances when ART is
failing to suppress viral replication is considerably different from nucleic acid testing
on pooled blood samples to identify instances of acute HIV infection. Specifically,
more efficient algorithms are needed because of the higher prevalence of instances of
virologic failure, the inherent variability of the viral load assay, and the need to
identify lower viral load levels. In this report, we demonstrate how screening for HIV
RNA among pooled blood samples can be used to monitor for active HIV replication
during ART in order to identify individuals who are experiencing virologic failure.
These results could have profound impact on the ability to virologically monitor HIVinfected patients receiving ART in resource constrained settings and ultimately limit
the development and transmission of drug resistant HIV strains.
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2. METHODS
Simulations were used to generate sample values of viral loads that represent a
population of patients on ART. The distribution of viral load values of the simulated
population was based on a natural history cohort of HIV infected individuals. Briefly,
for viral load values below 500 copies/mL, 85%, 5% and 10% of values were
generated to be uniformly distributed below 50 copies/mL, between 50 and 100
copies/mL and between 100 and 500 copies/mL, respectively. For values above 500
copies/mL, simulated viral load values were based on two gamma distributions with
modes at about 1000 and 6000 copies/mL (on log10 scale the gamma location
parameter was 2.7, scale parameter was 0.5 and shape parameter was 1.6 for the first
and 3.18 for the second gamma distribution). The proportion of values generated for
the first and second gamma distribution were 93% and 7% respectively. Both
individual and pooled values were generated to include measurement error from viral
load assay variability based on normally distributed measurement error with mean
zero. Assay standard deviation was assumed to be zero, 0.12 and 0.20 on the log10
scale. The value of zero represented a best case scenario, the value of 0.12 was based
on published data (Brambilla et al., 1999) and 0.20 represented a more conservative
alternative (Jagodzinski et al., 2000). Threshold values to define virologic failure
during ART of 500, 1000 or 1500 copies/mL were used based on clinically
meaningful thresholds at which drug resistance testing could be performed and
decisions to amend therapy might be expected (Harrigan et al., 2005; Haupts et al.,
2003; Hirsch et al., 2003).
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Three algorithms were evaluated (Figures 1 and 2). The first was based on
Dorfman’s (Dorfman, 1943) two-stage “minipool” approach where a fixed number of
samples would be combined into one pool. If the pooled samples yielded an assay
value above the lower limit of interest for the pool (e.g. ≥50 copies/mL), then all
individual samples would be tested in the second stage. Samples of pools with assay
values below the lower limit of interest would be considered virologically suppressed
and no further tests would be performed. For the second algorithm, minipools would
be formed in the same manner as for Dorfman’s approach; however, if the pooled
samples yielded a viral load value above the lower limit of interest, then individual
samples would be tested consecutively (in random order) and subtracted from the
pooled sample estimate until the lower limit of interest for the pool was achieved. We
call this approach “minipool + algorithm”. The third approach applied a similar
algorithm to a k by k matrix. For this approach, samples would be organized in a
matrix structure and pools formed over k rows and k columns. Samples of pools
would be considered virologically suppressed if either the row or column pools
yielded values below the threshold of interest. After obtaining (k + k) values for pools
across rows and columns, individual samples would be consecutively tested based on
the order of highest column and row value, i.e. the individual sample that resides in
the matrix at the intersection of the row and column pools with the highest viral load
values would be tested individually. Viral load values from the individual test would
then be subtracted from the appropriate column and row pool totals, and individual
testing would proceed one sample at a time until no further row and column pools
had values above the lower level of interest. If a single row (or column) showed a
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value above the lower limit of interest, but none of the columns (or rows) did, all
samples from such a row (or column) would be considered virologically suppressed.
Based on various prevalences of and thresholds for defining virologic failure, we
compared relative efficiency and negative predictive value for four approaches
(individual samples, minipool, minipool + algorithm and matrix approach) and
various pool sizes within each of the pooling approaches (minipool, minipool +
algorithm and matrix approaches). Relative efficiency was defined as one minus the
average number of assays performed divided by the number of samples. We use a
different definition of efficiency than others (Westreich, et al., 2008) because of the
natural interpretation that the best algorithm will have the highest values of efficiency
relative to individual testing. With this definition, an algorithm with efficiency zero
has no advantage over individual testing and an algorithm with efficiency of 0.25
uses 25% fewer samples than would be used with individual testing.
Negative predictive values were compared for the various approaches to identify
individual samples that had viral load values below the same range of thresholds
(500, 1000 and 1500 HIV RNA copies/mL) similar to the comparisons of relative
efficiency. For our purposes, the negative predictive value was the proportion of
individuals who were virologically suppressed below the threshold of interest (true
and test negative) among those who were considered suppressed by each proposed
method (test negative).
Additionally, we evaluated the various approaches in the context of the following
clinically relevant factors: 1) level of viral load for defining virologic failure, 2)
standard deviation of the viral load assay and 3) prevalence of virologic failure in the
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sampled population. Screening approaches for higher prevalence of virologic failure
and assays with larger standard deviation were expected to be less efficient than for
lower prevalence of virologic failure or assays with smaller standard deviation.
Pool sizes of 3, 4, 5, 6, 7, 8, 10 and 20 were considered. Since the lowest possible
level of viral load detection depends on the dilution factor of the pool, the level of
detection was considered in relation to the size of the pool. For example, with a lower
detection limit for a viral load assay of 50 copies/mL and a pool size of 10, the on
average lowest level of virologic failure that we can expect to detect for any
individual sample based on the pooled analysis was 500 copies/mL. When pools of
20 individual samples were considered, the lowest detectable level of virologic failure
was 1000 copies/mL. All simulations were run using the statistical software Stata
(StataCorp, 2007) and were repeated one thousand times for all conditions.

3. RESULTS
3.1 Relative efficiency
Of the three pooling approaches, most demonstrated relatively high efficiency
(>0.70) when the prevalence of virologic failure was low (<3%) (Figure 3), i.e. less
than 30% of viral load assays would be used in a pooling approach relative to
performing viral loads for each individual sample. When the prevalence of virologic
failure was higher (>3%), relative efficiency varied markedly, Dorfman’s (Dorfman,
1943) minipools showed lower relative efficiency than algorithms that used the
quantitative information available. A matrix approach with intermediate pool size (8
or 10) appeared to be the most efficient approach when: 1) virologic failure was
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defined as ≥1500 copies/mL, 2) the standard deviation of the assay was 0.12 and 3)
the prevalence of virologic failure of the sampled population was between 5% and
20%. Specifically, the relative efficiency for the matrix approach with a pool size of
10 ranged from 0.68 to 0.33 and for a matrix approach with a pool size of 8 it ranged
from 0.65 to 0.32 when the prevalence of virologic failure was 5% and 20%,
respectively. Among the approaches that use the minipools + algorithm, the one with
5 samples per pool appeared most efficient under similar conditions with relative
efficiency from 0.63 to 0.26 for a prevalence of virologic failure of 5% and 20%,
respectively. Thus, the relative efficiency of the 5 minipool+algorithm was close (no
more than 0.07 difference) to the most efficient matrix approaches. The relative
efficiency over the various approaches changed only slightly when the standard
deviation of the assay was 0.20. For example, when the prevalence of virologic
failure was 5% in the sampled population, the relative efficiency for the matrix
approach with a pool size of 10 was: 1) 0.66 when the standard deviation of the viral
load assay was 0.20, 2) 0.68 when the standard deviation was 0.12, and 3) 0.73 when
the standard deviation was zero. For Dorfman’s minipool approach, the most efficient
pool size was 3 (compare Dorfman (Dorfman, 1943), Table 1) with relative efficiency
ranging from 0.52 to 0.13 when the prevalence of virologic failure was 5% and 20%,
respectively.
Overall, pool sizes of 3 and 4 had the highest relative efficiency among the
minipool and minipool + algorithm approaches and a pool size of 10 had the highest
relative efficiency among the matrix approaches when the prevalence of virologic
failure was between 5% and 20% (Figure 4). Results were not substantially different
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when virologic failure was defined as ≥500, ≥1000 copies/mL or ≥1500 copies/mL.
For example, when using the matrix approach with a pool size of 10, assay SD of
0.12 and a prevalence of virologic failure of 20%, the relative efficiency was 0.68
when virologic failure was defined at ≥1500 copies/mL, 0.66 at ≥1000 copies/mL and
0.65 at 500 copies/mL.

3.2 Negative predictive values
The results for negative predictive values were uniformly good. For a prevalence
of virologic failure up to 10%, negative predictive values were at least 99% and 97%
for the matrix approach with assay standard deviations of 0.12 and 0.20 copies/mL
respectively. Similarly, the corresponding negative predictive values were 99% and
98% for all minipool + algorithm approaches. For a prevalence of virologic failure
up to 20%, negative predictive values were always at least 92% for all matrix
approaches and always above 96% for the minipool + algorithm approach when the
standard deviation of the assay was 0.12. These results changed only minimally for
an assay standard deviation of 0.20. Negative predictive values were always higher
than 99% for Dorfman’s minipool approach (without algorithm). These results
remained virtually unchanged for different definitions of virologic failure (500, 1000
and 1500 HIV RNA copies/mL).

3.3 Other factors
In addition to relative efficiency and negative predictive value, there are other
factors which can influence the clinical utility of these approaches. One is the local

http://biostats.bepress.com/uwbiostat/paper343

11

Comparison of Pooling Algorithms

need of turnaround time of the results, which will depend on availability of the
assays, personnel performing the assays and size of the clinical population receiving
ART. The proposed pooling strategies will vary in the time from sample collection to
the time individual viral load results are available to the clinician for management of
their patients. For example, if a laboratory has the capability of performing 20 viral
loads a day, then 20 individuals could be screened daily using individual viral load
testing and it would take 5 days to screen 100 individuals. If minipools of size 5 are
used, then 100 individuals could be screened in the first day, but some pools would
require additional testing and, therefore, additional days would be required before
results are available. The number of additional days would depend on the prevalence
of virologic failure in the sampled population and the specific pooling approach.
When 100 patients are screened using minipools of size 5 + algorithm and virologic
failure is defined as ≥1500 HIV RNA copies/mL and the prevalence of virologic
failure is 10%, there would be an average of 2 days until the viral loads of all samples
have been resolved. Similarly, the initial screening of the same 100 patients using the
matrix approach with a pool size of 10 would require one day, but the complete
resolution of all samples would require on average 28 days (1 day for testing all row
and column pools and an average of about 27 days for 27 individual assays that must
be tested consecutively); however, on average 65% of the individual samples would
have been resolved on the first day.
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4. DISCUSSION
Because commercial viral load assays cost between US $50.00–$150.00 per test
[Clinton Foundation. Diagnostics pricing. Available at:
<http://www.clintonfoundation.org/cf-pgm-hs-ai-work3.htm>; Accessed May 23,
2008. (Fiscus, et al., 2006)] the costs of virologic monitoring during ART may
exceed those of ART itself, but the development and transmission of drug resistant
HIV may ultimately compromise the effectiveness of ART in many populations
(Harrigan, et al., 2005; Haupts, et al., 2003; Little et al., 2002; Miller and Larder,
2001; Vijayaraghavan et al., 2007). In resource-constrained settings less expensive
methods to monitor viral replication during ART are necessary to make such
monitoring feasible and ART sustainable. In this report, we demonstrate how nucleic
acid testing on pooled blood samples can be used to reduce the overall number of
viral load tests needed to screen patients receiving ART compared to individual
testing.
Since the prevalence of virologic failure in the sampled population will impact the
relative efficiency and accuracy of the presented pooling and testing methods, other
strategies that can identify individuals with virologic failure before nucleic acid
testing could greatly increase the usefulness of the proposed methods. Such strategies
include the measurement of adherence to ART (Bisson, et al., 2008; Gifford et al.,
2000; Haubrich et al., 1999; Paterson et al., 2000) or longitudinal trajectory of CD4
counts (Bisson, et al., 2008); however, these methods are by no means perfect
predictors of virologic failure (Bisson, et al., 2008; Bisson, et al., 2006; Fiscus, et al.,
2006; Moore, et al., 2006; Petti, et al., 2006); and will need to be evaluated in
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individual clinical settings. Additionally, the definition of virologic failure is an
obvious factor in determining the prevalence of virologic failure in a population.
Although some research considers the consequences of different definitions of
virologic failure (Macias et al., 2005; Raboud et al., 1999; Raboud et al., 1998), it
remains unclear which level of HIV RNA viral load constitutes the most important
clinical cutpoint to define virologic failure. Differences regarding negative predictive
values between different definitions of virologic failure (500, 1000 and 1500 HIV
RNA copies/mL) appear to be very small (≤2%) and reasonably small (≤7%) for
prevalence of virologic failure up to 10% and 20% respectively. Differences in
relative efficiency for different definitions of virologic failure (500, 1000 and 1500
HIV RNA copies/mL) were also small. In essence, results regarding relative
efficiency and negative predictive value did not depend on the definition of virologic
failure. It might be possible to further improve the efficiency of the matrix approach
(e.g. choosing and individual testing of the cell with largest column and row pool;
subtracting individual test values from column and row estimates might not be
optimal).
Since the goal of virologic monitoring during ART, is to achieve and maintain a
low prevalence of virologic failure in the population of patients receiving ART,
another option to achieve low prevalence would be to monitor the population for
virologic failure at shorter intervals. Recent HIV treatment guidelines recommend
monitoring viral loads every three to four months (Hammer, et al., 2006); however,
these recommendations are based solely on expert’s interpretation of the published
literature (Hammer, et al., 2006), and more frequent monitoring has been proposed
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based on prospective clinical trial data (Haubrich, et al., 2001). More likely, the
frequency of virologic monitoring needed to optimize clinical outcomes will vary by
clinical setting, which would include factors such as the potency, tolerability and
durability of the available ART regimens, support available for patient adherence and
prevalence of transmitted drug resistance. Taken together, the methods used to
monitor for virologic failure during ART will need to be evaluated based on the needs
of each clinical setting.
Similarly, each clinical program will most likely have unique requirements for
assay characteristics (overall costs, turnaround time of results and monitoring
accuracy). For example, in some areas the overall cost of performing a viral load may
be the greatest limiting factor for monitoring for virologic failure; therefore, a clinical
program in this setting might best be served by a method that has the highest relative
efficiency for the assays, independent of the turnaround time of individual results or
maximal accuracy. Alternatively, other programs might require more rapid
turnaround times for obtaining viral load results, such as programs with smaller
patient populations receiving ART. These settings would require more time to obtain
enough samples to constitute a pool, and more frequent testing or smaller pool sizes
or even individual viral load testing might be the most cost-effective. Another factor
that must be considered for each clinical setting is quality assurance, which will
mostly depend on the expertise of the personnel performing the assays (sample
handling, processing and technical consistency with the viral load assay), which
could lead to errors in pooling, resolution testing and inconsistency in calculating
viral load results. Similar to choosing a method to screen for virologic failure, the
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extent and nature of technical training required to perform various pooling
approaches and maximize quality assurance will need to be evaluated in each local
laboratory and clinical setting.
We present characteristics for a variety of algorithms and pool sizes that can
incorporate available quantitative viral load data and data on how pooling methods
can be used efficiently and accurately to monitor for virologic failure in patients
receiving ART. These data could be used by individual laboratory and clinical
settings to make choices about optimal local virologic monitoring strategies. They
may also be used to design efficient pooling strategies for other settings where
screening involves quantitative measures. Although promising, further investigation
in resource-constrained settings is required to determine if these methods are feasible
and cost-effective with respect to the factors that could not be included in the
simulations like turnaround time of results, additional personnel costs in local
settings, and individual and public health costs of a patient population with virologic
failure during ART.
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Figure 1: Schematic overview of minipool and minipool + algorithm approaches.
Each circle represents an individual sample, each hexagon a pooled sample. The
numbers within the non-shaded circles are viral load values measured in the
individual samples. Green circles indicate individual samples that will have viral
loads measured in the next step. Yellow circles indicate samples that might have viral
loads measured depending on the outcome of the measures for the green circles.
In step 1 for the minipool approach (A), individual samples (green circles) are
pooled (hexagon) and a viral load measured in the pooled sample. In this example,
since the pooled sample is greater than the threshold of interest (here ≤300 copies/mL
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because there are 5 individual samples in a pool), then all individual samples are
tested individually in step 2.
In step 1 for the minipool + algorithm approach (B), individual samples (green and
yellow circles) are pooled (hexagon) and a viral load measured in the pooled sample.
In steps 2-4, since the pooled sample is greater than the threshold of interest,
individual samples of pools with values above the threshold are consecutively tested
and individual estimates (divided by pool size) are subtracted from pool total
(hexagon) until the threshold value is reached (red hexagon). Remaining samples
(grey circles) that have not been tested individually are assumed to be below
threshold (here ≤1500 copies/mL). Note, estimated values for individual samples will
typically not add up to estimated values for pooled samples because of assay
variability.
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Figure 2: Schematic overview of matrix approach. Each circle represents an
individual sample, each hexagon a pooled sample. The numbers within the nonshaded circles are viral load values measured on individual samples. Viral load values
for grey circles are assumed to be below the threshold (here ≤1500 copies/mL). Green
circles indicate samples that will be measured in the next step. Yellow circles indicate
samples that might be measured depending on the outcome of the measures for the
individual samples marked by the green circles. Red circles and hexagons indicate
that no further testing/estimation will be performed for the sample or pool. Note,
estimated values for individual samples will typically not add up to estimated values
for pooled samples because of assay variability.
In step 1 of the matrix approach, individual samples (circles) are pooled across
rows and columns (hexagons), and viral loads are then measured in each pool. All
individual samples are considered to be below the threshold level (grey circle) if their
respective row or column pool has a viral load below the threshold level of interest.
Individual samples that belong to a row and a column pool that have viral loads
above the threshold remain ambiguous as to whether or not they contain viral loads
above the threshold of interest and might be tested individually (green and yellow
circles). In step 2, the individual sample that belongs to the intersection of the row
and column pools with the highest viral load values (green circle) has its viral load
measured. The viral load of this individual sample is divided by the size of the pools
(here 5), and this value is subtracted from the respective row and column pool totals
(hexagons), and this subtraction can resolve previously ambiguous samples (yellow
circles) to be considered below the viral load level of interest (grey circles). In step 3,
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this continues until all individual samples belong to a row or column pool that has
reached the threshold level.

In this example the first individual sample that is tested has a viral load of 9935.
This value divided by the pool size (9935/5 = 1987) is subtracted from column (1522
– 1987 < 0) and row estimate (1718 – 1987 < 0). Samples or rows and columns with
pool estimates below the threshold (here ≤300) are not tested individually and are
assumed to be below the threshold (here ≤1500).
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Figure 3: Relative efficiency of minipool, minipool + algorithm and matrix
approaches for various pool sizes using a definition of virologic failure of HIV RNA
≥1500 copies/mL and assay standard deviation (SD) 0.12 copies/mL (on log10 scale).
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Figure 4: Relative efficiency for minipool, minipool + algorithm and matrix
approaches with highest (among different pool sizes) relative efficiency compared to
individual testing using a definition of virologic failure of viral load ≥1500 copies/mL
and assay standard deviation (SD) 0.12 copies/mL (on log10 scale).
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